lymphocytes

[Portage Biotech Inc.] Portage Biotech Inc., announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase I/II, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell agonist IMM60 developed for the treatment of solid tumors.

[Molecular Therapy] Scientists isolated a broad range of promising TCRs targeting multiple antigens for treatment of B-cell malignancies. 28 target genes for B-cell malignancies were selected based on gene expression profiles.

[Molecular Therapy] Investigators outline how epigenetic modifications in CAR T cells can overcome barriers limiting CAR T cell effectiveness, particularly in immunosuppressive tumor microenvironments.

[Nature Communications] The authors utilized an engineered microbial organism with a six-letter semi-synthetic DNA code to generate a library of site-specific, click chemistry compatible amino acid substitutions in the human cytokine IL-2.

[Oncogene] Researchers explored the inhibitory role of ITLN1 in the tumor-permissive microenvironment that existed during the first occurrence and subsequent development of colorectal carcinoma.

[GeekWire] Sonoma Biotherapeutics has raised $265 million in new funding which will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, type 1 diabetes, and IBD.